Metastatic Breast Cancer Clinical Trial
Official title:
A Phase 1b, Open-label, Non-randomized Trial for the Assessment of Safety, Tolerability, and Pharmacokinetics of OB-002 as a Monotherapy in Patients With Refractory Metastatic Colorectal, Pancreatic, Gastric, Breast, or Urothelial Cancer
Verified date | July 2023 |
Source | Orion Biotechnology Polska Sp. z o.o. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open-label, non-randomized trial with OB-002 monotherapy dose escalation followed by a dose expansion in patients with metastatic colorectal, pancreatic, gastric, breast, or urothelial cancer who have progressed on two or more treatment regimens.
Status | Not yet recruiting |
Enrollment | 36 |
Est. completion date | August 2025 |
Est. primary completion date | April 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Written informed consent. 2. Patients at least 18 years of age on the day of providing consent. 3. Patients with accessible metastatic lesions for repetitive biopsy retrieval. 4. Patients with histologically or cytologically confirmed metastatic colorectal, pancreatic, gastric, breast, or urothelial tumors who have progressed or were intolerant after two or more regimens and for whom no standard of care or curative therapy options are available. 5. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 within 7 days of the start of treatment 6. Patients with evaluable and measurable lesions as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 7. Patients with adequate organ function at the time of enrollment as defined below: 1. Neutrophil count =1500/mm3 2. Platelet count =7.5 × 105/mm3 3. Hemoglobin >9.0g/dL (transfusion >2 weeks before testing permitted) 4. Aspartate transaminase (AST), alanine transaminase (ALT) =2.5 × the upper limit of normal (ULN) (=5-times in patients with liver metastasis) 5. Total bilirubin =1.5 × ULN 6. Creatinine clearance >60 mL (determined by Cockcroft-Gault Equation) 7. International normalized ratio (INR) =1.5 × ULN and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) 8. In women with the potential for pregnancy (including patients with amenorrhea due to medical reasons, such as chemical menopause), after consenting to the study, the patient must agree to use contraception from enrollment and for at least 12 weeks after taking the final dose of the investigational drug. Women with the potential for pregnancy include those who have begun menstruation, who have not undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy, and who have not gone through menopause. Menopause is defined as the consecutive absence of menstrual periods for =12 months. Total abstinence is an acceptable mode of contraception. 9. In the case of men, the patient must agree after consenting to the study to use contraception from enrollment and for at least 13 weeks after taking the final dose of the investigational drug (a period of 90 days [the spermatogenesis cycle] is added to 5-times the elimination half-time of I/O agent. Total abstinence is an acceptable mode of contraception. Exclusion criteria: 1. Unwilling to undergo biopsy retrieval during screening (unless an archival sample taken within 3 months before screening is available) and after the fourth infusion of OB-002 2. Patients who have undergone systemic chemotherapy, radiotherapy, surgery, or hormone therapy <28 days before enrollment, also see exclusion criterion #8. Note: Patients must have recovered from all AEs due to previous therapies to =Grade 1 or baseline. Patients with =Grade 2 neuropathy may be eligible. If patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment. 3. Patients with a history of CCR5 antagonist therapy (e.g., vicriviroc, maraviroc). 4. Patients with uncontrolled hypertension (systolic blood pressure =150 mmHg or diastolic blood pressure =90 mmHg) with treatment 5. QTc interval greater than 450 msec (males) or 470 msec (females) 6. Patients with acute coronary syndrome (including myocardial infarction and unstable angina), and with a history of coronary angioplasty or stent placement performed within 6 months before enrollment 7. Patients with a large amount of pleural effusion or ascites requiring more than weekly drainage 8. Patients with a history of (non-infectious) pneumonitis that required steroids or have current pneumonitis. 9. Patients with a =Grade 3 active infection according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 10. Patients with symptomatic brain metastasis (1-week washout is permitted for palliative radiation (=2 weeks of radiotherapy) to non-central nervous system [CNS] disease) 11. Patients with partial or complete gastrointestinal obstruction 12. Patients with interstitial lung disease requiring treatment with systemic steroids or other agents 13. Patients who test positive for either anti-human immunodeficiency virus type 1 (HIV-1) antibodies, hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus (HCV) antibodies with a positive HCV RNA viral load test 14. Patients with concurrent autoimmune disease, or a history of chronic or recurrent autoimmune disease 15. Patients who require systemic corticosteroids equivalent to =10 mg prednisone (excluding temporary usage for tests, prophylactic administration for allergic reactions, or to alleviate swelling associated with radiotherapy) or immunosuppressants, or who have received such a therapy <14 days before enrollment in the present study 16. Patients with a history or findings of =Grade 3 congestive heart failure according to the New York Heart Association functional classification 17. Patients with a seizure disorder who require pharmacotherapy 18. Persistent proteinuria >3.5 g/24 hours measured by urine protein-creatinine ratio from a random urine sample (=Grade 3, NCI CTCAE v5.0) 19. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation 20. Major surgical procedure or significant traumatic injury within 28 days before the start of study medication 21. Non-healing wound, non-healing ulcer, or non-healing bone fracture 22. Patients with evidence or history of any bleeding diathesis, irrespective of severity 23. Any hemorrhage or bleeding event =Grade 3 (NCI CTCAE v 5.0) within 4 weeks prior to the start of the study medication 24. Women who are pregnant or breastfeeding, or with the potential for pregnancy unwilling to undergo contraception 25. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of the study drug |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Orion Biotechnology Polska Sp. z o.o. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Exploratory: immunogenicity of OB-002 | A number of patients developing antidrug antibodies (ADA) and the titers developed in these participants. | From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | |
Other | Exploratory: evaluation of receptor occupancy (RO) of OB-002 in blood | Percent of CCR5 receptors occupied by OB-002 in blood | samples are collected from first to fourth infusion (period of 28 days +/- 2 days) | |
Other | Exploratory: evaluation of receptor occupancy (RO) of OB-002 in tumor | Percent of CCR5 receptors occupied by OB-002 in tumor biopsies | samples are collected from first to fourth infusion (period of 28 days +/- 2 days) | |
Other | Exploratory: preliminary efficacy of OB-002 as monotherapy based on best overall response | Objective response rate (ORR): defined as the proportion of patients having best overall response (BOR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by the investigator. | From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months, assessed up to 12 months | |
Other | Exploratory: preliminary efficacy of OB-002 as monotherapy based on complete response | Objective response rate (ORR): defined as the proportion of patients having complete response (CR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by the investigator. | From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months, assessed up to 12 months | |
Other | Exploratory: preliminary efficacy of OB-002 as monotherapy based on partial response | Objective response rate (ORR): defined as the proportion of patients having a partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by the investigator. | From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months, assessed up to 12 months | |
Other | Exploratory: preliminary efficacy of OB-002 as monotherapy based on Progression-free survival | Progression-free survival (PFS): defined as the time from randomization until objective tumor progression or death, whichever comes first by RECIST v1.1 | From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months, assessed up to 12 months | |
Other | Exploratory: evaluation of OB-002 on blood biomarkers (immune cells) | Systemic monitoring of circulating immune cells | From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | |
Other | Exploratory: evaluation of OB-002 on blood biomarkers (cytokines) | Systemic monitoring of secreted cytokines. | From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | |
Other | Exploratory: evaluation of OB-002 on blood biomarkers (chemokines) | Systemic monitoring of secreted chemokines. | From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | |
Other | Exploratory: evaluation of OB-002 on tumor biomarkers (tumor-associated immune cells in TMI) | Examination of tumor-associated immune cells in tumor microenvironment | From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | |
Other | Exploratory: evaluation of OB-002 on blood biomarkers (TCR) | Genomic analyses on whole blood/peripheral blood mononuclear cells (PBMC) for T-cell repertoire (TCR) analyses | From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | |
Other | Exploratory: evaluation of OB-002 on blood biomarkers (ctDNA) | Plasma circulating tumor DNA (ctDNA) analysis | From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | |
Primary | Safety: adverse events | Number of patients experiencing adverse events (AEs), serious AEs (SAEs) abnormalities in clinical laboratory tests, vital signs, electrocardiograms (ECGs), and physical exams | From date of screening until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | |
Primary | Safety: Maximum Tolerated Dose | MTD will be defined on the basis of dose-limiting toxicities (DLTs) | From date of first infusion with 28 days observation period (+/-3 days) | |
Secondary | (PK) Pharmacokinetics Cmax | To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with maximum observed concentration (Cmax) profile of OB-002 in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer. | samples are collected from first to fourth infusion (period of 28 days +/- 2 days) | |
Secondary | (PK) Pharmacokinetics Tmax | To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with time to maximum serum concentration (Tmax) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer. | samples are collected from first to fourth infusion (period of 28 days +/- 2 days) | |
Secondary | (PK) Pharmacokinetics AUC0-t | To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with area under the curve from time 0 to last sampling time (AUC0-t) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer. | samples are collected from first to fourth infusion (period of 28 days +/- 2 days) | |
Secondary | (PK) Pharmacokinetics AUC0 8 | To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with area under the curve from time 0 to infinity (AUC0 8) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer. | samples are collected from first to fourth infusion (period of 28 days +/- 2 days) | |
Secondary | (PK) Pharmacokinetics t1/2 | To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with terminal half-life (t1/2) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer. | samples are collected from first to fourth infusion (period of 28 days +/- 2 days) | |
Secondary | (PK) Pharmacokinetics Vd | To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with the volume of distribution (Vd) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer. | samples are collected from first to fourth infusion (period of 28 days +/- 2 days) | |
Secondary | (PK) Pharmacokinetics CL | To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with clearance (CL) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer. | samples are collected from first to fourth infusion (period of 28 days +/- 2 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04872608 -
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
|
Phase 1 | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT02506556 -
Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05534438 -
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
|
Phase 2 | |
Recruiting |
NCT03368729 -
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT04103853 -
Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer
|
Phase 1 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Active, not recruiting |
NCT03147287 -
Palbociclib After CDK and Endocrine Therapy (PACE)
|
Phase 2 | |
Not yet recruiting |
NCT06062498 -
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05383196 -
Onvansertib + Paclitaxel In TNBC
|
Phase 1/Phase 2 | |
Recruiting |
NCT04095390 -
A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04432454 -
Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
|
Phase 2 | |
Recruiting |
NCT03323346 -
Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05744375 -
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
|
Phase 2 | |
Completed |
NCT02924883 -
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy
|
Phase 2 | |
Completed |
NCT01942135 -
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
|
Phase 3 | |
Completed |
NCT01881230 -
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04448886 -
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
|
Phase 2 | |
Completed |
NCT01401959 -
Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
|
Phase 2 | |
Terminated |
NCT04720664 -
Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer
|
Phase 2 |